Report Thumbnail
Product Code LP0913310471SCP
Published Date 2023/2/8
English127 PagesGlobal

Global Cell Therapy Regenerative Medicine Market Growth 2023-2029Pharmaceutical_LifeSciense Market


Report Thumbnail
Product Code LP0913310471SCP◆The Feb 2026 edition is also likely available. We will check with the publisher immediately.
Published Date 2023/2/8
English 127 PagesGlobal

Global Cell Therapy Regenerative Medicine Market Growth 2023-2029Pharmaceutical_LifeSciense Market



Abstract


Summary

Cell therapy is the use of stem cells or their derivatives to promote the repair of diseased, dysfunctional or damaged tissue. As technology develops, researchers can grow stem cells in the lab to differentiate into specific types of cells such as heart muscle cells, blood cells or nerve cells. This is a type of cell that helps repair damaged tissues or organs.
LPI (LP Information)' newest research report, the “Cell Therapy Regenerative Medicine Industry Forecast” looks at past sales and reviews total world Cell Therapy Regenerative Medicine sales in 2022, providing a comprehensive analysis by region and market sector of projected Cell Therapy Regenerative Medicine sales for 2023 through 2029. With Cell Therapy Regenerative Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cell Therapy Regenerative Medicine industry.
This Insight Report provides a comprehensive analysis of the global Cell Therapy Regenerative Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cell Therapy Regenerative Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Cell Therapy Regenerative Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cell Therapy Regenerative Medicine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cell Therapy Regenerative Medicine.
The global Cell Therapy Regenerative Medicine market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Cell Therapy Regenerative Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Cell Therapy Regenerative Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Cell Therapy Regenerative Medicine is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Cell Therapy Regenerative Medicine players cover DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure and Cellular Dynamics International, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Cell Therapy Regenerative Medicine market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
NK Cell Therapy
CAR-T Cell Therapy
Others
Segmentation by application
Dermatology
Cardiovascular
Central Nervous System
Plastic Surgery
Other Medical Applications
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
DePuy Synthes
Medtronic
ZimmerBiomet
Stryker
Acelity
MiMedx Group
Organogenesis
UniQure
Cellular Dynamics International
Osiris Therapeutics
Vcanbio
Gamida Cell
Golden Meditech
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
Stemcell Technologies
Bellicum Pharmaceuticals
Key Questions Addressed in this Report
What is the 10-year outlook for the global Cell Therapy Regenerative Medicine market?
What factors are driving Cell Therapy Regenerative Medicine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Cell Therapy Regenerative Medicine market opportunities vary by end market size?
How does Cell Therapy Regenerative Medicine break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Table of Contents

  • 1 Scope of the Report

    • 1.1 Market Introduction
    • 1.2 Years Considered
    • 1.3 Research Objectives
    • 1.4 Market Research Methodology
    • 1.5 Research Process and Data Source
    • 1.6 Economic Indicators
    • 1.7 Currency Considered
    • 1.8 Market Estimation Caveats
  • 2 Executive Summary

    • 2.1 World Market Overview
      • 2.1.1 Global Cell Therapy Regenerative Medicine Annual Sales 2018-2029
      • 2.1.2 World Current & Future Analysis for Cell Therapy Regenerative Medicine by Geographic Region, 2018, 2022 & 2029
      • 2.1.3 World Current & Future Analysis for Cell Therapy Regenerative Medicine by Country/Region, 2018, 2022 & 2029
    • 2.2 Cell Therapy Regenerative Medicine Segment by Type
      • 2.2.1 NK Cell Therapy
      • 2.2.2 CAR-T Cell Therapy
      • 2.2.3 Others
    • 2.3 Cell Therapy Regenerative Medicine Sales by Type
      • 2.3.1 Global Cell Therapy Regenerative Medicine Sales Market Share by Type (2018-2023)
      • 2.3.2 Global Cell Therapy Regenerative Medicine Revenue and Market Share by Type (2018-2023)
      • 2.3.3 Global Cell Therapy Regenerative Medicine Sale Price by Type (2018-2023)
    • 2.4 Cell Therapy Regenerative Medicine Segment by Application
      • 2.4.1 Dermatology
      • 2.4.2 Cardiovascular
      • 2.4.3 Central Nervous System
      • 2.4.4 Plastic Surgery
      • 2.4.5 Other Medical Applications
    • 2.5 Cell Therapy Regenerative Medicine Sales by Application
      • 2.5.1 Global Cell Therapy Regenerative Medicine Sale Market Share by Application (2018-2023)
      • 2.5.2 Global Cell Therapy Regenerative Medicine Revenue and Market Share by Application (2018-2023)
      • 2.5.3 Global Cell Therapy Regenerative Medicine Sale Price by Application (2018-2023)
  • 3 Global Cell Therapy Regenerative Medicine by Company

    • 3.1 Global Cell Therapy Regenerative Medicine Breakdown Data by Company
      • 3.1.1 Global Cell Therapy Regenerative Medicine Annual Sales by Company (2018-2023)
      • 3.1.2 Global Cell Therapy Regenerative Medicine Sales Market Share by Company (2018-2023)
    • 3.2 Global Cell Therapy Regenerative Medicine Annual Revenue by Company (2018-2023)
      • 3.2.1 Global Cell Therapy Regenerative Medicine Revenue by Company (2018-2023)
      • 3.2.2 Global Cell Therapy Regenerative Medicine Revenue Market Share by Company (2018-2023)
    • 3.3 Global Cell Therapy Regenerative Medicine Sale Price by Company
    • 3.4 Key Manufacturers Cell Therapy Regenerative Medicine Producing Area Distribution, Sales Area, Product Type
      • 3.4.1 Key Manufacturers Cell Therapy Regenerative Medicine Product Location Distribution
      • 3.4.2 Players Cell Therapy Regenerative Medicine Products Offered
    • 3.5 Market Concentration Rate Analysis
      • 3.5.1 Competition Landscape Analysis
      • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
    • 3.6 New Products and Potential Entrants
    • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Cell Therapy Regenerative Medicine by Geographic Region

    • 4.1 World Historic Cell Therapy Regenerative Medicine Market Size by Geographic Region (2018-2023)
      • 4.1.1 Global Cell Therapy Regenerative Medicine Annual Sales by Geographic Region (2018-2023)
      • 4.1.2 Global Cell Therapy Regenerative Medicine Annual Revenue by Geographic Region (2018-2023)
    • 4.2 World Historic Cell Therapy Regenerative Medicine Market Size by Country/Region (2018-2023)
      • 4.2.1 Global Cell Therapy Regenerative Medicine Annual Sales by Country/Region (2018-2023)
      • 4.2.2 Global Cell Therapy Regenerative Medicine Annual Revenue by Country/Region (2018-2023)
    • 4.3 Americas Cell Therapy Regenerative Medicine Sales Growth
    • 4.4 APAC Cell Therapy Regenerative Medicine Sales Growth
    • 4.5 Europe Cell Therapy Regenerative Medicine Sales Growth
    • 4.6 Middle East & Africa Cell Therapy Regenerative Medicine Sales Growth
  • 5 Americas

    • 5.1 Americas Cell Therapy Regenerative Medicine Sales by Country
      • 5.1.1 Americas Cell Therapy Regenerative Medicine Sales by Country (2018-2023)
      • 5.1.2 Americas Cell Therapy Regenerative Medicine Revenue by Country (2018-2023)
    • 5.2 Americas Cell Therapy Regenerative Medicine Sales by Type
    • 5.3 Americas Cell Therapy Regenerative Medicine Sales by Application
    • 5.4 United States
    • 5.5 Canada
    • 5.6 Mexico
    • 5.7 Brazil
  • 6 APAC

    • 6.1 APAC Cell Therapy Regenerative Medicine Sales by Region
      • 6.1.1 APAC Cell Therapy Regenerative Medicine Sales by Region (2018-2023)
      • 6.1.2 APAC Cell Therapy Regenerative Medicine Revenue by Region (2018-2023)
    • 6.2 APAC Cell Therapy Regenerative Medicine Sales by Type
    • 6.3 APAC Cell Therapy Regenerative Medicine Sales by Application
    • 6.4 China
    • 6.5 Japan
    • 6.6 South Korea
    • 6.7 Southeast Asia
    • 6.8 India
    • 6.9 Australia
    • 6.10 China Taiwan
  • 7 Europe

    • 7.1 Europe Cell Therapy Regenerative Medicine by Country
      • 7.1.1 Europe Cell Therapy Regenerative Medicine Sales by Country (2018-2023)
      • 7.1.2 Europe Cell Therapy Regenerative Medicine Revenue by Country (2018-2023)
    • 7.2 Europe Cell Therapy Regenerative Medicine Sales by Type
    • 7.3 Europe Cell Therapy Regenerative Medicine Sales by Application
    • 7.4 Germany
    • 7.5 France
    • 7.6 UK
    • 7.7 Italy
    • 7.8 Russia
  • 8 Middle East & Africa

    • 8.1 Middle East & Africa Cell Therapy Regenerative Medicine by Country
      • 8.1.1 Middle East & Africa Cell Therapy Regenerative Medicine Sales by Country (2018-2023)
      • 8.1.2 Middle East & Africa Cell Therapy Regenerative Medicine Revenue by Country (2018-2023)
    • 8.2 Middle East & Africa Cell Therapy Regenerative Medicine Sales by Type
    • 8.3 Middle East & Africa Cell Therapy Regenerative Medicine Sales by Application
    • 8.4 Egypt
    • 8.5 South Africa
    • 8.6 Israel
    • 8.7 Turkey
    • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends

    • 9.1 Market Drivers & Growth Opportunities
    • 9.2 Market Challenges & Risks
    • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis

    • 10.1 Raw Material and Suppliers
    • 10.2 Manufacturing Cost Structure Analysis of Cell Therapy Regenerative Medicine
    • 10.3 Manufacturing Process Analysis of Cell Therapy Regenerative Medicine
    • 10.4 Industry Chain Structure of Cell Therapy Regenerative Medicine
  • 11 Marketing, Distributors and Customer

    • 11.1 Sales Channel
      • 11.1.1 Direct Channels
      • 11.1.2 Indirect Channels
    • 11.2 Cell Therapy Regenerative Medicine Distributors
    • 11.3 Cell Therapy Regenerative Medicine Customer
  • 12 World Forecast Review for Cell Therapy Regenerative Medicine by Geographic Region

    • 12.1 Global Cell Therapy Regenerative Medicine Market Size Forecast by Region
      • 12.1.1 Global Cell Therapy Regenerative Medicine Forecast by Region (2024-2029)
      • 12.1.2 Global Cell Therapy Regenerative Medicine Annual Revenue Forecast by Region (2024-2029)
    • 12.2 Americas Forecast by Country
    • 12.3 APAC Forecast by Region
    • 12.4 Europe Forecast by Country
    • 12.5 Middle East & Africa Forecast by Country
    • 12.6 Global Cell Therapy Regenerative Medicine Forecast by Type
    • 12.7 Global Cell Therapy Regenerative Medicine Forecast by Application
  • 13 Key Players Analysis

    • 13.1 DePuy Synthes
      • 13.1.1 DePuy Synthes Company Information
      • 13.1.2 DePuy Synthes Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.1.3 DePuy Synthes Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.1.4 DePuy Synthes Main Business Overview
      • 13.1.5 DePuy Synthes Latest Developments
    • 13.2 Medtronic
      • 13.2.1 Medtronic Company Information
      • 13.2.2 Medtronic Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.2.3 Medtronic Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.2.4 Medtronic Main Business Overview
      • 13.2.5 Medtronic Latest Developments
    • 13.3 ZimmerBiomet
      • 13.3.1 ZimmerBiomet Company Information
      • 13.3.2 ZimmerBiomet Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.3.3 ZimmerBiomet Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.3.4 ZimmerBiomet Main Business Overview
      • 13.3.5 ZimmerBiomet Latest Developments
    • 13.4 Stryker
      • 13.4.1 Stryker Company Information
      • 13.4.2 Stryker Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.4.3 Stryker Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.4.4 Stryker Main Business Overview
      • 13.4.5 Stryker Latest Developments
    • 13.5 Acelity
      • 13.5.1 Acelity Company Information
      • 13.5.2 Acelity Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.5.3 Acelity Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.5.4 Acelity Main Business Overview
      • 13.5.5 Acelity Latest Developments
    • 13.6 MiMedx Group
      • 13.6.1 MiMedx Group Company Information
      • 13.6.2 MiMedx Group Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.6.3 MiMedx Group Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.6.4 MiMedx Group Main Business Overview
      • 13.6.5 MiMedx Group Latest Developments
    • 13.7 Organogenesis
      • 13.7.1 Organogenesis Company Information
      • 13.7.2 Organogenesis Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.7.3 Organogenesis Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.7.4 Organogenesis Main Business Overview
      • 13.7.5 Organogenesis Latest Developments
    • 13.8 UniQure
      • 13.8.1 UniQure Company Information
      • 13.8.2 UniQure Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.8.3 UniQure Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.8.4 UniQure Main Business Overview
      • 13.8.5 UniQure Latest Developments
    • 13.9 Cellular Dynamics International
      • 13.9.1 Cellular Dynamics International Company Information
      • 13.9.2 Cellular Dynamics International Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.9.3 Cellular Dynamics International Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.9.4 Cellular Dynamics International Main Business Overview
      • 13.9.5 Cellular Dynamics International Latest Developments
    • 13.10 Osiris Therapeutics
      • 13.10.1 Osiris Therapeutics Company Information
      • 13.10.2 Osiris Therapeutics Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.10.3 Osiris Therapeutics Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.10.4 Osiris Therapeutics Main Business Overview
      • 13.10.5 Osiris Therapeutics Latest Developments
    • 13.11 Vcanbio
      • 13.11.1 Vcanbio Company Information
      • 13.11.2 Vcanbio Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.11.3 Vcanbio Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.11.4 Vcanbio Main Business Overview
      • 13.11.5 Vcanbio Latest Developments
    • 13.12 Gamida Cell
      • 13.12.1 Gamida Cell Company Information
      • 13.12.2 Gamida Cell Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.12.3 Gamida Cell Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.12.4 Gamida Cell Main Business Overview
      • 13.12.5 Gamida Cell Latest Developments
    • 13.13 Golden Meditech
      • 13.13.1 Golden Meditech Company Information
      • 13.13.2 Golden Meditech Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.13.3 Golden Meditech Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.13.4 Golden Meditech Main Business Overview
      • 13.13.5 Golden Meditech Latest Developments
    • 13.14 Cytori
      • 13.14.1 Cytori Company Information
      • 13.14.2 Cytori Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.14.3 Cytori Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.14.4 Cytori Main Business Overview
      • 13.14.5 Cytori Latest Developments
    • 13.15 Celgene
      • 13.15.1 Celgene Company Information
      • 13.15.2 Celgene Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.15.3 Celgene Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.15.4 Celgene Main Business Overview
      • 13.15.5 Celgene Latest Developments
    • 13.16 Vericel Corporation
      • 13.16.1 Vericel Corporation Company Information
      • 13.16.2 Vericel Corporation Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.16.3 Vericel Corporation Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.16.4 Vericel Corporation Main Business Overview
      • 13.16.5 Vericel Corporation Latest Developments
    • 13.17 Guanhao Biotech
      • 13.17.1 Guanhao Biotech Company Information
      • 13.17.2 Guanhao Biotech Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.17.3 Guanhao Biotech Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.17.4 Guanhao Biotech Main Business Overview
      • 13.17.5 Guanhao Biotech Latest Developments
    • 13.18 Mesoblast
      • 13.18.1 Mesoblast Company Information
      • 13.18.2 Mesoblast Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.18.3 Mesoblast Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.18.4 Mesoblast Main Business Overview
      • 13.18.5 Mesoblast Latest Developments
    • 13.19 Stemcell Technologies
      • 13.19.1 Stemcell Technologies Company Information
      • 13.19.2 Stemcell Technologies Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.19.3 Stemcell Technologies Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.19.4 Stemcell Technologies Main Business Overview
      • 13.19.5 Stemcell Technologies Latest Developments
    • 13.20 Bellicum Pharmaceuticals
      • 13.20.1 Bellicum Pharmaceuticals Company Information
      • 13.20.2 Bellicum Pharmaceuticals Cell Therapy Regenerative Medicine Product Portfolios and Specifications
      • 13.20.3 Bellicum Pharmaceuticals Cell Therapy Regenerative Medicine Sales, Revenue, Price and Gross Margin (2018-2023)
      • 13.20.4 Bellicum Pharmaceuticals Main Business Overview
      • 13.20.5 Bellicum Pharmaceuticals Latest Developments
  • 14 Research Findings and Conclusion

USD 3,660 or Partial Purchase
*Prices are subject to change by the publisher.
© 2026 ShareFair Inc.